FluidAI Medical announces an acquisition deal with Emmetros Limited

FluidAI announces the acquisition of Emmetros, enhancing patient engagement with Stream Inara™ and innovative AI solutions.
Researchers discover new antibiotic for IBD and AI correctly predicts how it works

Learn how researchers from Stoked Bio are discovering new antibiotics for IBD using AI-based drug discovery solutions.
McMaster startup NodeAI delivers more accurate lung cancer diagnoses

McMaster University startup NodeAI is bringing more accurate lung cancer diagnoses using ultrasound imaging instead of repeated biopsies.
FluidAI secures a $2-million Government of Canada investment to accelerate global commercialization of AI-driven postoperative care technology

FluidAI Medical has secured an investment of $2 million from the Government of Canada to enhance its AI-driven postoperative care technology.
13171229 B.C. Ltd. and Launchit Solutions Inc. Announce Execution of Business Combination Agreement and Launchit’s Concurrent Financing

Launchit Solutions enters business combination with 13171229 B.C. Ltd., to become a public traded company, enhancing capital access and market presence.
iGan Partners leads Seed+ financing for Cosm Medical to advance personalized gynecological devices

Cosm Medical, backed by iGan Partners, is set to advance personalized pelvic health with AI-driven, 3D-printed Gynethotics™ device.
Restoring Independence After Stroke with IRegained Inc.

Read the Hamilton Health Innovation Checkup recap with IRegained to learn about their journey and how they leveraged the Hamilton ecosystem.
Canadian innovation revolutionizes menstrual health worldwide with the Bfree Cup – The world’s first boil-free, antibacterial menstrual cup

The Bfree Cup is a game-changing antibacterial menstrual cup that promotes gender equity and combats period poverty.
FluidAI leading the way in AI-driven post-operative care

Learn how FluidAI is revolutionizing patient outcomes with AI-powered post-operative care and support for recovery.
University spin-out Afynia secures $5M seed to commercialize its microRNA panel test for endometriosis

Discover how Afynia Laboratories secured a $5 million seed round to commercialize its microRNA panel test for endometriosis.